Medline Inc. IPO Raises Over $7 Billion, Analysts Initiate Coverage
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: Benzinga
- IPO Success: Medline closed its IPO in December 2025, raising over $7 billion by offering 248.44 million shares at $29 each, marking the largest IPO globally in 2025 and significantly enhancing its market position.
- Market Leadership: Analysts highlight Medline's leadership in the U.S. medical-surgical product manufacturing and distribution sector, projecting sustainable high-single-digit organic growth driven by market share gains and strong demand.
- Positive Analyst Ratings: Firms like Bank of America and BTIG initiated coverage with 'Buy' ratings and a price target of $50, indicating a 23% potential upside, reflecting strong market confidence in Medline's growth prospects.
- Enhanced Financial Flexibility: Post-IPO, Medline plans to pay down $4 billion in debt, leaving approximately $1 billion for potential M&A or international expansion, further solidifying its competitive edge in a $375 billion addressable market.
Analyst Views on MDLN
Wall Street analysts forecast MDLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDLN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 43.410
Low
Averages
High
Current: 43.410
Low
Averages
High
No data
About MDLN
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
